NCT00045279View on ClinicalTrials.gov

PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

April 30, 2002

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

PEG-interferon alfa-2b

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00045279 - PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter